Autopsy report · NCT01038856

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

“The study was terminated by the sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 2 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 4 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Oklahoma

Sponsor type

University, hospital or other

Conditions

Polycythemia Vera

Interventions

Erlotinib

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  “This study was terminated by the Sponsor.” (98% match in meaning)
• Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
  “Study terminated by the Sponsor” (96% match in meaning)
• A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
  “The study was terminated early as per Sponsor's decision” (95% match in meaning)
• Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
  “The Sponsor terminated the study.” (95% match in meaning)
• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
  “Study was terminated based on Sponsor decision” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.